Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-vectored H5N1 Influenza Candidate Vaccine - Ad4-H5-Vtn.
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2013
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- 31 Jan 2013 Results were published online in Lancet Infectious Diseases, and were reported in a PaxVax media release.
- 02 Mar 2012 Additional lead trial investigator (Marc Gurwith) identified as reported by ClinicalTrials.gov.
- 02 Mar 2012 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History